The extracellular proteoglycanase ADAMTS-1 has critical roles in organogenesis and angiogenesis. We demonstrate here the functional convergence of ADAMTS-1 and the transmembrane heparan sulfate proteoglycan syndecan-4 in influencing adhesion, migration, and angiogenesis in vitro. Knockdown of ADAMTS-1 in fibroblasts and endothelial cells resulted in a parallel reduction in cell surface syndecan-4 that was not due to altered syndecan-4 expression or internalization, but was attributable to increased expression and activity of matrix metalloproteinase-9 (MMP-9), a known syndecan-4 sheddase. Knockdown of either syndecan-4 or ADAMTS-1 led to enhanced endothelial cell responses to exogenous vascular endothelial growth factor (VEGF), and increased microvessel sprouting in ex vivo aortic ring assays, correlating with reduced ability of the cells to sequester VEGF. On fibronectin but not type 1 collagen matrices, endothelial cells with knockdown of either ADAMTS-1 or syndecan-4 elicited increased migration and showed similarly altered focal adhesion (FA) morphologies, with a higher proportion of larger FA's and formation of long fibrillar integrin α5-containing FA's. However, integrin α5-null endothelial cells also displayed enhanced migration in response to ADAMTS-1/syndecan-4 knockdown, indicating that integrin α5 was not the mediator of the altered migratory behaviour. Plating of naïve endothelial cells on cellconditioned matrix from ADAMTS-1/syndecan-4 knockdown cells demonstrated that the altered behaviour was matrix dependent. Fibulin-1, a known ECM co-factor of ADAMTS-1, was expressed at reduced levels in ADAMTS-1/syndecan-4 knockdown cells. These findings support the notion that ADAMTS-1 and syndecan-4 are functionally interconnected in regulating cell migration and angiogenesis, via the involvement of MMP-9 and fibulin-1 as collaborators
Introduction
The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of extracellular proteases includes 19 members in humans, with diverse roles in tissue development and homeostasis (Kuno et al., 1997; Porter et al., 2005) . Their essential functions are underlined by the recognition that several family members encode genes which are responsible for inherited genetic disorders when mutated, while others are associated with pathologies including cancer, arthritis and cardiovascular disease when aberrantly expressed (Hubmacher and Apte, 2015; Kelwick, Desanlis, et al., 2015; Mead and Apte, 2018) .
The ADAMTSs are zinc-dependent metalloproteinases with a compound domain structure, each possessing a catalytic domain containing the metalloproteinase and disintegrin-like features, followed by a modular ancillary domain that differs between sub-groups of family members and is important for their biological actions (Kuno et al., 1997; Porter et al., 2005) .
The largest clade in the ADAMTS family are identified as proteoglycanases that can cleave a variety of proteoglycans, including versican, aggrecan, brevican, as well as other extracellular matrix proteins (Hubmacher and Apte, 2015; Kelwick, Desanlis, et al., 2015) . First discovered in 1997, ADAMTS-1 is the prototype of the family and a member of the proteoglycanase clade which also includes . The ability of ADAMTS-1 to cleave structural ECM components is physiologically relevant as demonstrated by Adamts1-knockout mice, which exhibit abnormally high rates of perinatal lethality due to multiple organ defects, in particular severe kidney malformation and cardiac defects (De et al., no date; Krampert et al., 2005) The surviving female mice suffer from infertility, due to the ineffective cleavage of versican during ovarian maturation (Shindo et al., 2000; Mittaz et al., 2004; Krampert et al., 2005) .
However, as well as its proteolytic function, ADAMTS-1 also interacts with other proteins including latent TGF- (Bourd-Boittin et al., 2011) and fibulin-1, which acts as a co-factor (Lee et al., 2005) . ADAMTS-1 has many context-dependent effects in biological processes such as migration, invasion and cell signalling, which are relevant to its impact on physiology and pathophysiology (De et al., no date) , indicating it acts through multiple mechanisms. This is reflected in its anti-angiogenic actions, which involve both proteolytic and non-proteolytic mechanisms, the former by mediating the release of highly anti-angiogenic fragments of thrombospondin-1 (TSP1) and TSP-2 (Lee et al., 2006; Gustavsson et al., 2010) and the latter via direct binding and sequestration of vascular endothelial growth factor VEGF165 Fu et al., 2011) .
Another significant proteoglycan partner of ADAMTS-1 is syndecan-4(Rodríguez- Manzaneque et al., 2009) . Syndecan-4 is a ubiquitously expressed heparan-sulfate proteoglycan that acts as a key mediator of several cellular processes including adhesion, proliferation and endocytosis (Couchman and Woods, 1999; Elfenbein et al., 2012; Elfenbein and Simons, 2013) . Its heparan-sulfate glycosaminoglycan (GAG) chains provide binding sites for heparin-binding growth factors such as fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs) and vascular endothelial growth factors (VEGFs) (Elfenbein and Simons, 2013) . The binding of these growth factors to syndecan-4 can have several consequences: activation of cellular signalling can occur through syndecan-4 acting as a coreceptor that presents the growth factor ligand to its signalling receptor, as in the case of FGF, or there can be direct activation of downstream signalling mediated by syndecan-4 itself, such as PKC-α Couchman, 1997b, 1997a) . In addition, syndecan-4 can regulate growth factor bioavailability by acting as a cell-bound reservoir that can be released by subsequent proteolytic cleavage (Bergers et al., 2000; Ramnath et al., 2014) . But besides its role as a signalling regulator, syndecan-4 is also a key mediator in focal adhesion formation.
Fibroblasts from syndecan-4 null mice exhibit impaired adhesion to fibronectin (Ishiguro et al., 2000) . Via the binding and activation of protein kinase C  (PKC), syndecan-4 facilitates 51 integrin binding to its substrate fibronectin, allowing maturation of focal adhesions (Mostafavi-Pour et al., 2003; Bass et al., 2007) . Given its key role as a nexus of signalling and adhesion mechanisms, the relative levels and localisation of syndecan-4 are therefore critical determinants of cellular behaviour.
Several reports have connected the actions of ADAMTS enzymes with syndecan-4 (SDC4), including ADAMTS-1 and -4(Rodríguez-Manzaneque et al., 2009) , ADAMTS-5 (Echtermeyer et al., 2009; Wang et al., 2011) , ADAMTS-6 and -10(Cain et al., 2016) and ADAMTS-15 (Kelwick, Wagstaff, et al., 2015) . In this study, we have uncovered details of a complex inter-relationship between ADAMTS-1 and syndecan-4 in murine fibroblasts and endothelial cells. We have shown that acute depletion of ADAMTS-1 leads to a concomitant reduction in cell surface levels of syndecan-4, such that down-regulation of either syndecan-4 or ADAMTS-1 have similar consequences on cell behaviour, shown by increases in cellular migration and striking changes to focal adhesions, both of which were fibronectin-dependent. Furthermore, loss of either ADAMTS-1 or syndecan-4 in endothelial cells led to increases in angiogenesis which we demonstrate is due to reduced ability of cells to sequester the pro-angiogenic growth factor VEGF. Moreover, these effects have downstream consequences on 5 integrin trafficking, but 5 integrin is not essential for them to occur. These results demonstrate the existence of an interplay between ADAMTS-1 and syndecan-4 which orchestrates cell adhesion, migration and angiogenesis.
Results

Knockdown of ADAMTS-1 results in reduction of cell surface syndecan-4
We have used siRNA to deplete either ADAMTS-1 or Syndecan-4 in murine 3T3 fibroblast cell line (3T3s) and lung microvascular polyoma middle T-antigen immortalised endothelial cells (ECs). mRNA knockdown was confirmed using TaqMan qPCR ( Figure S1 ). Our initial hypothesis was that since ADAMTS-1 has been reported to cleave the N-terminal domain of syndecan-4, depletion of ADAMTS-1 would result in accumulation of syndecan-4 on the cell surface (Rodríguez-Manzaneque et al., 2009) . However, flow cytometric analysis revealed that siRNA knockdown of ADAMTS-1 resulted in a significant concomitant decrease in cell surface syndecan-4, equivalent to that seen with syndecan-4 knockdown ( Figure 1A ). To confirm this visually, immunocytochemistry was performed, however as in our hands staining using commercially available syndecan-4 antibody was unsuccessful, cells were transfected with a HA-tagged syndecan-4 construct (HA-SDC4). This confirmed reduced cell surface HA-SDC4 display in ADAMTS-1-depleted cells when compared to cells treated with non-targeting control siRNA ( Figure 1B ).
To elucidate the mechanism by which ADAMTS-1 regulates syndecan-4 expression, we first investigated whether knockdown of ADAMTS-1 led to changes in Sdc4 gene expression.
ADAMTS-1 siRNA did not alter Sdc4 expression at the RNA level ( Figure s1 ). Therefore, we hypothesised that loss of cell surface syndecan-4 could be a result of changes in membrane trafficking, so we carried out cell surface biotinylation-based internalization and recycling assays. ECs were surface-labelled with cleavable biotin, incubated for time points to allow internalisation, then biotin remaining on the cell surface was cleaved. Syndecan-4 internalisation was quantified by a syndecan-4 capture ELISA and biotin detection using streptavidin ( Figure 1C ). For the recycling assay cells were incubated further, to allow biotinylated protein to recycle to the surface ( Figure 1D ). These experiments demonstrated that neither the rate of syndecan-4 internalization or levels of recycling to the membrane were changed as a result of ADAMTS-1 knockdown.
Loss of cell surface syndecan-4 is MMP9 dependent
Since reduced syndecan-4 levels did not appear to be a result of altered transcription or membrane trafficking, we speculated that the decreased cell surface syndecan-4 was a result of increased shedding. As MMPs are known cleavers of syndecans they were considered as possible mediators of this shedding (Manon-Jensen, Itoh and Couchman, 2010) . ECs were treated with one of the following three broad-spectrum MMP inhibitors: BB-94, CT-1746, GM 6001 or a DMSO vehicle control. Treatment with any of the three MMP inhibitors resulted in accumulation of syndecan-4 at the cell surface, and in cells treated with ADAMTS-1 siRNA, syndecan-4 levels recovered to match that of the NTC cells ( Figure 2A ). This suggests that MMPs are responsible for the reduction in cell surface syndecan-4 seen in response to loss of ADAMTS-1.
To identify the specific enzyme responsible, a panel of MMPs known to be expressed in endothelial cells were profiled: MMP2, MMP9, MMP14 (MT1-MMP) and ADAMTS-4 (Bergers et al., 2000; Genís et al., 2006; Hsu et al., 2012) . ADAMTS-1 siRNA knockdown resulted in significantly increased expression of MMP9 compared to NTC or syndecan-4 siRNA treated cells, which expressed almost no MMP9. In both treated and untreated cells, MMP2, MMP14 and ADAMTS-4 expression was unchanged ( Figure 2B ). The increase in MMP9 RNA expression was reflected in increased MMP9 activity, as shown by gelatin zymography of conditioned media from ADAMTS-1 siRNA, syndecan-4 siRNA and NTC treated cells ( Figure 2C ). In these experiments we were unable to detect syndecan-4 that had been shed from the cell surface into the media under any conditions, indicating that this is likely rapidly degraded. However treatment with MMP9 siRNA ( Figure 2D ) or an MMP9 specific inhibitor SB-3CT ( Figure 2E ) was sufficient to reverse the phenotype resulting from ADAMTS-1 knockdown. This demonstrates that increased expression of MMP9, known to cleave syndecan-4 is directly responsible for the reduced syndecan-4 levels seen after ADAMTS-1 siRNA treatment (Ramnath et al., 2014; Reine et al., 2019) .
Syndecan-4 contributes to ADAMTS-1's sequestration of VEGF
ADAMTS-1 acts as an inhibitor of angiogenesis by sequestering VEGF165, a key proangiogenic factor. This sequestration prevents VEGF from binding and activating its major receptor VEGFR2 . ADAMTS-1 exclusively binds VEGF165, and the interaction is dependent on the heparin binding domain. Previous work by Iruela-Irispe et al has suggested that a heparin sulphate proteoglycan such as a member of the syndecan family may provide a bridge to facilitate this interaction(IRUELA-ARISPE, .
The impact of ADAMTS-1 or syndecan-4 siRNA on VEGF signalling was investigated.
Endothelial cells were serum-starved for 3 hours, then stimulated with 30ng/mL VEGF164 (the mouse equivalent of human VEGF165). Cells were lysed at 0, 5, 15 and 30 minutes post stimulation and lysates collected were run on a Western blot to look for changes in the VEGF signalling pathway. Upon siRNA knockdown of either ADAMTS-1 or syndecan-4, increased phospho-VEGFR2 and phospho-ERK were seen, indicating an increase in cellular responsiveness to exogenous VEGF when ADAMTS-1 or syndecan-4 levels are reduced ( Figure 3A , figure S2 ).
In order to test the hypothesis that syndecan-4 may be aiding ADAMTS-1's sequestration of VEGF, co-immunoprecipitations were performed. An IP for VEGF was able to co-precipitate syndecan-4, revealing that syndecan-4 either directly or indirectly binds VEGF. When cells were treated with ADAMTS-1 siRNA, less syndecan-4 was found upon co-precipitation ( Figure 3B , 3C). The reduction in syndecan-4 seen with ADAMTS-1 siRNA may be an indicator that the interaction involves ADAMTS-1, however it may also be a result of the reduced cell surface syndecan-4 seen with ADAMTS-1 siRNA treatment.
As both ADAMTS-1 and syndecan-4 are capable of binding VEGF, the relevance of these interactions was investigated using a VEGF ELISA to assess how much VEGF cells were able to sequester. As before, 30 ng/mL VEGF was added to ECs cooled to 4C to prevent signalling.
A Western blot was performed to confirm that signalling pathways were not activated ( figure   S2A ), and qPCR confirmed VEGF RNA levels were unchanged ( figure S2B ). The cells were kept at 4C for 30 minutes to allow binding. The media was then collected and an ELISA was performed to quantify the amount of unbound VEGF remaining in the media. When cells were treated with ADAMTS-1, syndecan-4 or both siRNAs, the amount of free VEGF remaining in the media significantly increased ( Figure 3D ). Taken together then, these data suggest that the loss of ADAMTS-1 or syndecan-4 prevents the sequestration of VEGF, leaving it freely available to activate downstream signalling pathways.
ADAMTS-1 and syndecan-4 sequestration of VEGF inhibits angiogenesis
The physiological relevance of the ability of ADAMTS-1 and syndecan-4 to sequester VEGF was next investigated. The process of angiogenesis requires both proliferation and migration of endothelial cells, which can be stimulated by VEGF. BrdU labelling of siRNA treated cells revealed increased proliferation in ADAMTS-1-depleted cells, but not syndecan-4-depleted ( Figure 4A ). As syndecan-4 is known to interact with numerous other growth factors (FGFs, EGFs, PDGFs) this may be a result of multiple pathway involvement (Harburger and Calderwood, 2008) .
As conflicting reports exist with regards to the roles of ADAMTS-1 and syndecan-4 in cell migration (Krampert et al., 2005; Bass et al., 2007; Rodríguez-Manzaneque et al., 2009; Obika et al., 2012) , random migration assays were carried out on siRNA-depleted cells to assess effects of their knockdown on motility. siRNA-treated endothelial cells were plated on either 10 µg/mL collagen I or 10 µg/mL fibronectin and time-lapse microscopy was performed over a period of 16 hours to track cell migration. Migration speed was significantly increased with both ADAMTS-1 and syndecan-4 on fibronectin matrices only ( Figure 4B ).
To see if the altered proliferation and migration resulted in a corresponding increase in angiogenesis, the mouse aortic ring assay was utilised. Aortas were harvested from 6-8 weekold mice, sliced into rings and treated with siRNA against ADAMTS-1 or syndecan-4. The rings were embedded in matrix, and the number of sprouts that formed was used as a marker of angiogenesis (Baker et al., 2011) . Both siRNAs successfully depleted their targets in the aortic rings ( Figure 4C ). Both ADAMTS-1 and syndecan-4 depletion resulted in a marked increase in VEGF-dependent new vessel sprouting ( Figure 4D , 4E), demonstrating a physiologically relevant effect of the sequestration of VEGF by ADAMTS-1 and syndecan-4.
Adhesions are altered in ADAMTS-1/syndecan-4 siRNA cells on fibronectin matrices
As knockdown of either ADAMTS-1 or syndecan-4 led to altered migration speeds on fibronectin but not on collagen I, focal adhesions parameters were assessed on both matrices.
Cells were seeded on a collagen I or fibronectin matrix for 90 or 180 minutes. Staining for paxillin was performed to visually assess focal adhesions, and their size and number was calculated using ImageJ. While on both collagen and fibronectin the numbers of focal adhesions were unchanged in siRNA-depleted cells, adhesions to fibronectin matured more quickly. At 90 minutes post-adherence to fibronectin, the average focal adhesion size was larger, with a higher percentage of adhesions reaching a more mature stage ( Figure 5A , Figure   5B ). The majority of adhesions remained as small nascent adhesions (<2 µm 2 ) (NTC: 95.6%, syndecan-4: 90.9%, ADAMTS-1: 92%), however a higher percentage of cell adhesions in siRNA-treated cells had developed into focal adhesions (2-6 µm 2 ) (NTC: 4.3%, syndecan-4: 8.5%, ADAMTS-1: 7.2%). By 180 minutes this difference no longer existed, suggesting that the siRNA-treated cells do not form more large adhesions, rather their adhesions mature at a faster rate. Adhesions to collagen were unaffected ( Figure S4) , confirming that the observed effects are due to interaction with the fibronectin matrix. These changes in focal adhesions of ADAMTS-1 or syndecan-4 knockdown cells on fibronectin were also apparent in a marked increase in paxillin signalling in response to VEGF ( Figure 5C, figure S5 ). This supports the proposition that ADAMTS-1 and syndecan-4 act to sequester VEGF reducing its bioavailability, and that their depletion leads to enhanced VEGF signalling and subsequent changes to focal adhesion morphology.
Alpha 5 integrin localisation is disrupted in the absence of ADAMTS-1 or syndecan-4
Since our data showed perturbation of fibronectin-dependent adhesions following ADAMTS-1 or syndecan-4 depletion, the contribution of alpha 5 integrin (5), the major fibronectin receptor in nascent focal adhesions in endothelial cells, was considered. Immunocytochemical visualisation of 5 revealed the development of long, fibrillar-like adhesions after 180 minutes adherence to fibronectin in cells treated with ADAMTS-1 or syndecan-4 siRNA, as apposed to the more traditional 5 localisation in focal adhesions <6 µm 2 seen in NTC cells ( Figure 6A ).
As syndecan-4 is known to have a role in integrin surface trafficking, biotinylation-based internalisation assays were performed as before to assess 5 membrane trafficking (Morgan et al., 2013) . To quantify internalisation, immunoprecipitation of biotin followed by Western blot detection of 5 integrin was utilised. Western blotting revealed an increase in total cell surface 5 in ADAMTS-1 and syndecan-4 siRNA treated cells, as well as decreased levels of internalisation, suggesting the altered adhesions may be a result of 5 accumulation due to impaired internalisation ( Figure 6B, figure 6C ). To test whether this retention of α5 integrin on the cell surface in ADAMTS-1/ syndecan-4 knockdown cells was responsible for the altered cell characteristics we again performed the experiments above in 5-null endothelial cells treated with ADAMTS-1 or syndecan-4 siRNA. However, although 5-null endothelial cells showed reduced migration compared to their wild-type counterparts, the same phenotypes of increased rates of migration and focal adhesion maturation, and decreased VEGF sequestration following ADAMTS-1 or syndecan-4 knockdown were maintained ( Figure 6D ). These data suggest that the changes in 5 integrin seen are likely a downstream consequence of changes in cell behaviour mediated by ADAMTS-1/ syndecan-4 knockdown, rather than 5 integrin being the key effector of the phenotypes.
EC behaviour and signalling phenotypes are maintained in response to conditioned matrix.
As the mechanism by which ADAMTS-1 and syndecan-4 siRNA increased cell migration and changed focal adhesions was not dependent on integrin 5, modulation of the ECM itself was considered, especially since these responses were reliant on the cells being on a fibronectin matrix. In order to assess this, experiments were performed using 'conditioned matrix' (CM) from siRNA-treated cells that were seeded onto glass coverslips and allowed to produce matrix for 48 hours, following which the siRNA-treated cells were then stripped away, leaving behind CM. Untreated cells were then seeded onto the CM and left to adhere for 3 hours and immunocytochemistry for 5 integrin was carried out. The phenotype of long, fibrillar adhesions was repeated, indicating that 5 integrin changes occur in response to a modified matrix ( Figure 7A ). Signalling was examined in a similar fashion: untreated cells were adhered to CM for 45, 90 and 180 minutes, then cells were lysed and signalling responses examined.
Cells adhered to the conditioned matrix from ADAMTS-1 or syndecan-4 knockdown cells showed increased paxillin and ERK signalling, suggesting that the altered matrix is sufficient to induce the more migratory phenotype ( Figure 7B ).
Fibulin 1, a co-factor for ADAMTS-1 and a matrix protein which has been reported to inhibit migration showed enhanced expressed at 180 minutes post adhesion to fibronectin in NTC treated cells, but not ADAMTS-1 or syndecan-4 siRNA treated cells ( Figure 7C , figure   S7 ) (Twal et al., 2001; Lee et al., 2005) . These data support a mechanism by which ADAMTS-1 and syndecan-4 regulate adhesion by inducing expression of the matrix protein fibulin 1.
Discussion
Our work provides new insights into a functional connection between ADAMTS-1 and the cell surface proteoglycan syndecan-4. Knockdown of either protein via siRNA results in similar responses with regards to angiogenesis, cell migration, and integrin α5 trafficking. Our data support the notion that ADAMTS-1 is an inhibitor of angiogenesis, and we offer novel data that this occurs in co-ordination with syndecan-4.
Previous work has shown that ADAMTS-1 inhibits angiogenesis through direct sequestration of the major pro-angiogenic growth factor VEGF165, reducing its bioavailability ). This has also been shown to be true for ADAMTS-4, which can bind VEGF and inhibit angiogenesis in a similar fashion to ADAMTS-1 (Hsu et al., 2012) .
The heparin binding domain of VEGF165 is necessary for its interaction with ADAMTS-1, and work by Iruela-Arispe et al has suggested that this interaction may be reliant on a heparinlike molecule. One such candidate is syndecan-4, a heparan sulphate proteoglycan and the major syndecan in endothelial cells, known to interact with heparin-binding growth factors such as VEGFs, PDGFs and FGFs (Harburger and Calderwood, 2008) . Thus, given the numerous connections between ADAMTS-1 and syndecan-4 and the dependence of ADAMTS-15 on syndecan-4 to enhance migration ability, we sought to investigate the relationship between syndecan-4 and ADAMTS-1.
Importantly, ADAMTS-1 has been reported to cleave the ectodomain of syndecan-4, promoting migration in a way that reflects genetic deletion of the proteoglycan (Rodríguez-Manzaneque et al., 2009 ). However, we were unable to detect evidence of a cleaved form of syndecan-4 released from the fibroblasts and endothelial cells used in our studies. Instead we were able to demonstrate a convergent functional relationship between ADAMTS-1 and syndecan-4 since ADAMTS-1 siRNA treatment caused a significant reduction in syndecan-4 display at the cell surface, indicating that syndecan-4 is dependent on ADAMTS-1. A key finding from our work is that this connection between ADAMTS-1 and cell surface expression of syndecan-4 involves matrix metalloproteinase-9 (MMP-9).
Syndecan ectodomain shedding is an important regulatory mechanism allowing for rapid changes in cell surface receptor dynamics; shedding occurs juxtamembrane and can be carried out by a number of matrix proteinases(Manon-Jensen, Itoh and Couchman, 2010) . MMP7 and to shed syndecan-4 from the cell surface in response to TNFα (Kwon et al., 2014; Ramnath et al., 2014; Lee et al., 2017) . There was a significant increase in MMP9 expression in ADAMTS-1 siRNA-treated cells, and upon loss of MMP9, via either an inhibitor or siRNA-depletion, syndecan-4 was no longer lost from the cell surface. We therefore propose that the loss of ADAMTS-1 results in increased shedding of syndecan-4 that is mediated by MMP9.
At this point, we are not able to identify the mechanism by which ADAMTS-1 knockdown results in increased MMP9 expression. One possibility however is that it occurs as a result of a shift in the angiogenic signalling balance in endothelial cells. ADAMTS-1 is anti-angiogenic, whereas MMP9 is highly pro-angiogenic, and can trigger the 'angiogenic switch', a process in tumours where the balance of pro and anti-angiogenic factors swings towards a proangiogenic outcome (Bergers et al., 2000) . MMP9 promotes release of VEGF bound in the matrix to heparan-sulphate chains through cleavage (Hawinkels et al., 2008) . VEGF induces MMP9 expression which leads to elevated free VEGF levels resulting in a positive feedback loop (Hollborn et al., 2007) . Similarly, VEGF can upregulate ADAMTS-1 expressionsuggesting a negative feedback mechanism at play (Xu, Yu and Duh, 2006) . It seems possible that loss of ADAMTS-1 disturbs the fine balance of VEGF signalling, resulting in the cells switching to a more angiogenic phenotype, and the upregulation of MMP9.
We sought to investigate the possibility that syndecan-4 works co-operatively with ADAMTS-1 to inhibit angiogenesis through sequestration of VEGF. This idea contrasts with several hypotheses that syndecan-4 acts as a co-receptor for VEGF to enhance signalling, as is the case for FGFs. Through Co-IPs, we demonstrated that syndecan-4 does indeed bind VEGF. We interpret this binding as sequestration since an increase in VEGF signalling and free VEGF is seen upon syndecan-4 depletion. These data strongly suggest that syndecan-4 does not promote VEGF signalling, but instead alongside ADAMTS-1 sequesters VEGF to inhibit angiogenesis.
We further demonstrated this finding in a physiologically relevant ex vivo model of angiogenesis and observed increased micro-vessel sprouting in an aortic ring assay with ADAMTS-1 or syndecan-4 siRNA-depletion. It therefore seems plausible that MMP9, ADAMTS-1 and syndecan-4 work together in a complex equilibrium to balance VEGF bioavailability and regulate angiogenesis.
For angiogenesis to occur, endothelial cells must proliferate and migrate -processes that are heavily influenced by VEGF signalling. Loss of ADAMTS-1 resulted in increased proliferation, however this result was not mirrored with loss of syndecan-4. This implies that the two molecules have distinct as well as shared actions. On the one hand, syndecan-4 is a major signalling nexus involved as a partner in the actions of several growth factors as well as a source of intracellular signals itself. These multiple pathways could negate the impact of syndecan-4's sequestration of VEGF. Likewise, ADAMTS-1 functions independently of syndecan-4, specifically in relation to angiogenesis by releasing antiangiogenic peptides from TSP-1 and -2 TSP-2 through cleavage (Lee et al., 2006) . At the organism level, although Sdc4
and Adamts1 null mice share a delayed wound healing response (Echtermeyer et al., 2001) , the models do not phenocopy each other. Whilst Sdc4 knockout mice are relatively healthy, Adamts1 KO mice exhibit developmental issues with stunted growth and high embryonic mortality (Shindo et al., 2000; Echtermeyer et al., 2001) .
Previous work on fibroblasts from Sdc4-/-animals showed syndecan-4 was necessary for directional migration to occur , however in our experiments, acute depletion of syndecan-4 or ADAMTS-1 in endothelial cells resulted in increased migration speed. This observation was only seen on fibronectin, with decreased or no change in migration speed on collagen. Fibronectin matrix-dependent migration effects have been noted previously with the ADAMTSs; work by Kelwick et al showed that the closely related ADAMTS-15 was able to inhibit MDA-MB-231 cell migration on fibronectin matrices, and that this effect was dependent on syndecan-4 (Kelwick, Wagstaff, et al., 2015) . In endothelial cells, α5 integrin functions as the major fibronectin receptor. Interestingly, syndecan-4 regulates adhesion synergistically with fibronectin and α5β1 integrin (Morgan, Humphries and Bass, 2007) , as well as regulating integrin trafficking. Phosphorylation of syndecan-4 acts as a molecular switch, controlling levels of αVβ3 and α5β1 internalisation and recycling, and affecting cell behaviour (Morgan et al., 2013) .
Due to the clear connection between syndecan-4, fibronectin, and integrins, we sought to investigate α5 integrin as a potential mediator of migratory effects. Immunocytochemical and cell surface biotinylation data support an important role for syndecan-4 in regulation of α5 integrin trafficking. ADAMTS-1 knockdown also appeared to regulate α5 integrin trafficking, but whether this is a direct effect is unclear, though it would be consistent with the resulting loss of syndecan-4. Despite this, siRNA knockdowns of ADAMTS-1 and syndecan-4 repeated in α5 null endothelial cells maintained the phenotypes of increased VEGF signalling, increased free VEGF, faster random migration and larger focal adhesions, suggesting that α5 integrin is not necessary for ADAMTS-1 and syndecan-4 regulated angiogenesis and migration.
Therefore, we hypothesised that knockdowns of ADAMTS-1 and syndecan-4 may result in ECM alterations, resulting in downstream changes to integrin trafficking. Both proteins interact with the ECM: ADAMTS-1 is secreted and anchors in the ECM while syndecan-4 forms cell-ECM attachments (Kuno and Matsushima, 1998; Gopal et al., 2017) . In support of this, nontreated naïve cells plated on 'conditioned matrix' matrix created by ADAMTS-1/ syndecan-4 siRNA cells behaved in a similar manner to siRNA treated cells, forming altered α5 adhesions, and increased paxillin signalling.
Fibulin 1 is an ECM protein, and a co-factor for ADAMTS-1 (Lee et al., 2005) ; expression of fibulin 1 has been reported to result in a fibronectin-specific inhibition of migration in a cell type-dependent manner (Twal et al., 2001) . In fibroblasts, this effect is dependent on syndecan-4 (Williams and Schwarzbauer, 2009 ). Fibulin 1 is indeed upregulated at 180 minutes post adhesion in NTC-treated cells, but not in ADAMTS-1 or syndecan-4 siRNA cells. We therefore propose a mechanism for the control of migration in endothelial cells where ADAMTS-1/ syndecan-4 regulate production of fibulin 1, thereby suppressing migration and facilitating α5 integrin turnover.
This work builds on the current literature on ADAMTS-1 as an anti-angiogenic protein; demonstrating co-operation between ADAMTS-1 and the heparin sulphate proteoglycan syndecan-4. We highlight a role for syndecan-4 in inhibiting migration and angiogenesis, which contrasts with some previous published data. When attempting to understand conflicts with regards to syndecan-4 it is important to consider the model used. Much previous work has focused on the constitutive knockout mouse, and cells and tissues isolated from it (Echtermeyer et al., 2001) . Compensatory mechanisms from developmental adaptation to loss of syndecan-
In conclusion, our work shows that ADAMTS-1 regulates cell-surface expression of syndecan-4, and in endothelial cells both molecules act via sequestration of VEGF and inhibition of angiogenesis. ADAMTS-1 influences syndecan-4 levels on the cell surface via regulation of MMP9 production. Our studies also reveal convergent roles for ADAMTS-1 and syndecan-4 in regulating the ECM, inhibiting migration, modulating integrin adhesions and activating the matrix protein fibulin 1.
Materials and methods
Cell culture and isolation
Human umbilical vein endothelial cells (HUVECs) were cultured in EBM-2 media supplemented with the SingleQuotsTM kit (Lonza, Slough, UK). 3T3 fibroblasts were cultured in high glucose DMEM (invitrogen) supplemented with 10% fetal bovine serum (FBS) (HyClone, Invitrogen), 100 units/mL penicillin/streptomycin (Invitrogen), and 2 mM glutamax (Invitrogen).
Primary mouse lung endothelial cells were isolated from adult mice as previously described by Reynolds & Hodivala-Dilke(Reynolds and Hodivala-Dilke, 2006) . For immortalisation, ECs were treated with polyoma-middle-T-antigen (PyMT) retroviral transfection as described by Robinson et al(Robinson et al., 2009) . Immortalized mouse lung endothelial cells (ECs) were cultured in IMMLEC media, a 1:1 mix of Ham's F-12:DMEM medium (low glucose) supplemented with 10% FBS, 100 units/mL penicillin/streptomycin, 2 mM glutamax, 50 μg/mL heparin (Sigma).
All cells were cultured at 37°C in a humidified chamber with 5% CO2. For experimental analyses, plates and flasks were coated with either: human plasma fibronectin (FN) (Millipore), collagen I (Col I) (Fisher Scientific) overnight at 4°C. VEGF-A 164 (henceforth referred to as VEGF) was made in-house according to the method published by Krilleke et al (Krilleke et al., 2007) .
RNAi and lentiviral transfections
For siRNA transfections, ECs were transfected with 50nM siRNA (Thermo Scientific) using the Amaxa nucleofector system (Lonza) according to manufacturer's instructions, with a final siRNA concentration of 50nM, and the nucleofection program T-005. For syndecan-4 (SDC4) ICC and ELISA, ECs were transfected with HA-tagged SDC4 construct (a generous gift from James Whiteford). Transfected cells were selected for using a GFP reporter tag.
For shRNA knockdown of syndecan-4/ADAMTS-1 in HUVECs, packaging plasmids (Addgene) were mixed with shRNA plasmid (Mission shRNA, Sigma-Aldrich) in Optimem medium (Invitrogen) and Lipofectamine 2000 (Invitrogen) with the following ratios: 750 ng psPAX2, 250 ng pMD2.G, 1 μg shRNA. The mixture was transferred to 80% confluent 293T cells in 10cm dishes for 6 h. The medium was replaced with regular DMEM 10% FBS and collected after 48 h. Medium containing virus was filtered through a 0.45 μm filter and used for HUVEC transduction with the addition of 8 μg/mL polybrene (Sigma). The target sequences used were as follows: Human Sdc4 sequence: 
Flow cytometry
For flow-cytometric analysis, cells were removed from culture plates using citric saline buffer (1.35 M KCL, 0.15 M Na3C6H5O7). Cells were collected by centrifugation and resuspended in FACS buffer (5% FBS in PBS) and labelled with anti-mouse syndecan-4 (KY/8.2, BD Bioscience), or isotype control (Mouse IgG2a, Invitrogen) for 1 hour. Cells were washed, resuspended in FACS buffer and incubated with fluorophore-conjugated secondary antibody (eBioscience). Data was collected using a Beckman CytoFLEX and analysed using FlowJo.
For treatment with MMP inhibitors one of: 5 μM BB-94 (Abcam), 10 μM CT1746 (CellTech), 10 μM GM-6001 (Millipore) in 10 μL DMSO, or DMSO vehicle control, was added to cells for 18 hours prior to flow cytometric analysis.
RNA extraction, reverse transcription-PCR and real-time quantitative RT-PCR analyses
Total cell RNA was extracted using the SV Total RNA Isolation Kit (Promega) according to manufacturer's instructions. RNA samples were reverse transcribed using GoScript™ Reverse Transcriptase system (Promega). Quantitative real-time TaqMan PCR was carried out as described previously (López-Otín and Matrisian, 2007) .
Immunocytochemistry siRNA-transfected ECs were seeded at a density of 2x10 5 cells/well in 24 well plates on acidwashed and oven-sterilised glass coverslips pre-coated with FN or Col I. Cells were fixed at indicated time points in 4% paraformaldehyde, washed in PBS, blocked and permeabilised with 0.3% Triton X-100, 10% serum, and incubated with primary antibody diluted 1:100 in PBS for 1 h at RT. Primary antibodies were: anti-HA tag (Thermo, 2-2.2.14), anti-paxillin (ab32084; Abcam), anti-5 integrin (Abcam, ab150361). Coverslips were PBS washed, and incubated with the relevant Alexa-Fluor®-conjugated secondary antibody (Invitrogen) diluted 1:500 in PBS for 45 min at RT. Coverslips were washed in PBS again, before mounting on slides with Prolong® Gold containing DAPI (Invitrogen). Focal adhesion area calculations were carried out in FIJI™.
Internalisation and Recycling assays
Internalisation 1x10 6 siRNA transfected cells were seeded in 10 cm dishes. After adhering overnight, cells were serum starved for 3 hours, transferred to ice, washed twice in cold PBS, and surface labelled at 4°C with 0.3 mg/ml NHS-SS-biotin (Pierce) for 30 min. Labelled cells were washed in cold PBS and transferred to IMMLEC at 37°C to allow internalization. At each time point, medium was removed, dishes were transferred to ice and washed twice with ice-cold PBS.
Biotin was removed from proteins remaining at the cell surface by incubation with the membrane impermeable reducing agent MesNa (20 mM MesNa in 50 mM Tris-HCL (pH 8.6)) for 1 hour at 4°C. MesNa was quenched by the addition of 20 mM iodoacetamide (IAA) for 10 mins. Cells were lysed in 200 mM NaCl, 75 mM Tris, 15 mM NaF, 1.5 mM Na3VO4, 7.5 mM EDTA, 7.5 mM EGTA, 1.5% Triton X-100, supplemented with protease inhibitor (Merck).
Lysates were cleared by centrifugation at 10,000 × g for 10 min. Levels of syndecan-4internalisation were determined by capture ELISA. For 5 integrin internalisation analysis, biotinylated protein was isolated by immunoprecipitation using anti-biotin (Jackson Immunoresearch), and levels of 5 integrin assessed by SDS-PAGE.
Recycling
After surface labelling, cells were incubated in IMMLEC at 37°C for 20 minutes to allow internalization. Following removal of biotin from surface proteins using MesNA, the internalized fraction was then allowed to recycle to the membrane by returning cells to 37°C in IMMLEC. At the indicated times, cells were returned to ice and biotin was removed from recycled proteins by a second reduction with MesNa. Biotinylated syndecan-4 was then determined by capture-ELISA.
Capture-ELISA 96-well microplates (R&D Systems) were coated overnight with 5 μg/mL HA-tag antibody (51064, Proteintech) in PBS at room temperature. The plates were blocked in PBS containing 0.05% Tween-20 (0.05% PBS-T) with 1% BSA for 1 hr at room temperature. HA-SDC4 was captured by 2 hour incubation of 100 μl cell lysate (1 μg/μL) at room temperature. Unbound material was removed by extensive washing with 0.05% PBS-T. Wells were incubated with streptavidin-conjugated horseradish peroxidase (R&D Systems) in 0.05% PBS-T containing 1% BSA for 1 hr at room temperature. Following further washing, biotinylated SCD4 was detected with Tetramethylbenzidine (R&D systems).
Zymography
Zymography was performed using SDS-PAGE (7.5%) gels co-polymerized with 1 mg/ml gelatin. Protein concentration of media samples were equalized, and added to 5X non-reducing sample buffer (Thermo Scientific). After electrophoresis, gels were washed twice for 30 minutes in wash buffer (2.5% Triton X-100, 50 mM Tris HCl, 5 mM CaCl2, 1 μM ZnCl2) at room temperature. Gels were incubated overnight in incubation buffer (1% Triton X-100, 50 mM Tris-HCl, 5 mM CaCl2, 1 µM ZnCl2) at 37C. Gels were stained in Coomassie Blue R 250 (Thermo Fisher) in a mixture of methanol:acetic acid:water (4:1:5) for 1 hour and destained in the same solution without dye. Gelatinase activities were visualized as distinct bands.
Western blot analysis
ECs were seeded at 2.5x10 5 cells per well in 6 well plates coated with 10 μg/ml FN. After 24 hours, cells were starved for 3 hours in serum free medium (OptiMEM®; Invitrogen). VEGF was then added to a final concentration of 30 ng/ml. Cells were lysed at the indicated times (see main text) in RIPA buffer (25mM Tris, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, supplemented with protease inhibitor (Merck). After protein quantification using the DC BioRad assay, 30 μg of protein from each sample was loaded onto 8% polyacrylamide gels. For paxillin analysis, samples were loaded onto a 4-12% gradient gel for better resolution. The protein was transferred to a nitrocellulose membrane and incubated for 1 h in 5% milk powder/PBS plus 0.1% Tween-20 (0.1% PBS-T), followed by an overnight incubation in primary antibody diluted 1:1000 in 5% bovine serum albumin (BSA)/ 0.1% PBS-T) at 4°C. The blots were then washed 3x with 0.1% PBS-T and incubated with the relevant horseradish peroxidase (HRP)-conjugated secondary antibody (Dako) diluted 1:2000 in 5% milk/PBST, for 1 h at room temperature. Chemiluminescence was detected on a Bio-Rad Gel Doc XR + (Bio-Rad).
Antibodies (all used at 1:1000 and purchased from Cell Signaling Technology, unless noted otherwise) were: anti-phospho (Y1175) VEGFR2 (clone 19A10); anti-VEGFR-2 (clone 55B11); anti-phospho (Thr202/Tyr204) p44/42 MAPK Erk1/2 (clone D13.14.4E); anti-total p44/42 MAPK Erk1/2, anti-HSC70 (clone B-6, Santa Cruz Biotechnology), anti-human syndecan-4 (ab24511, abcam), anti-phospho (Tyr118) paxillin (2541), anti-phospho (Tyr925) FAK, anti-FAK, anti-GAPDH (6C5,abcam).
FIJI™ was used for quantification of band densities.
Immunoprecipitation assay
HUVECs were grown to 80-90% confluency in 10-cm dishes coated with 10 μg/ml FN in PBS.
Cells were lysed in RIPA buffer. 400 μg of total protein from each sample was immunoprecipitated by incubation with protein-G Dynabeads® (Invitrogen) coupled to a mouse-anti-human VEGF-A antibody (VG-1, Abcam) on a rotator overnight at 4°C.
Immunoprecipitated complexes were washed three times with 0.2 ml of RIPA buffer, and once in PBS, before being added to, and boiled in NuPAGE® sample reducing agent and sample buffer (Life Technologies) for Western blotting.
VEGF ELISA
For quantification of free VEGF present in the media, ECs were plated at a density of 2.5x10 5 cells per well of a 6 well plate. Cells were chilled to 4C, media was removed and cells were washed twice in ice cold PBS. Media was replaced with ice cold OptiMEM® containing VEGF at a final concentration of 30 ng/ml. Media was diluted 1:10 in 1% BSA in PBS, and VEGF concentration was quantified using a mouse VEGF duo-set ELISA, according to manufacturer's instructions (DY493, R&D systems).
Proliferation Assay
siRNA-transfected ECs were seeded on 10 μg/ml FN coated glass coverslips (1.5x10 4 cells/well of a 24 well plate). After 4 hours, the media was replaced with IMMLEC containing 10nM BrdU. After 12 hours cells were fixed in 4% PFA. To stain, cells were incubated in 1M HCL for 30 mins at room temperature, then permeabilized with PBS 0.25% triton X-100 for 10 minutes and blocked by a 20 minute incubation in DAKO block (Agilent). BrdU was detected by incubation with anti-BrdU (ICR1, Abcam) diluted 1:100 in PBS for 1 hour at room temperature. Coverslips were washed in PBS, then incubated with anti-sheep Alexa-Fluor® (Invitrogen) for 1 hour at room temperature. After further PBS washes, coverslips were mounted in pro-long gold® containing DAPI (invitrogen).
Random-migration assay
siRNA-transfected ECs were trypsinised and seeded at 1.5x10 4 cells/well in 24-well plates coated with 10 μg/ml FN or 10 μg/ml Col I in PBS, and allowed to adhere overnight. The media was then replaced fresh IMMLEC. One phase contrast image/well was taken live every 10 min in a fixed field of view using an inverted Axiovert (Zeiss) microscope for 16 h at 37°C and 5% CO2. Individual cells were then manually tracked using the FIJI™ cell tracking plugin, mTrackJ and the speed of random migration was calculated in nm moved/seconds.
Ex vivo aortic ring assay
Thoracic aortae were isolated from 6 to 8 week-old adult mice and prepared for culture as described extensively by Baker et al (Baker et al., 2011) . Syndecan-4 or ADAMTS-1 depletion was induced using 1 μM siRNA and oligofectamine. Where indicated, VEGF was added at 30 ng/mL. Microvessel growth of aortic rings was quantified after 6-10 days.
Conditioned matrix generation
For experiments using conditioned matrix (CM), siRNA treated cells were seeded at ~70% confluence and allowed to produce matrix for 48 hours. Plates were washed in PBS and cells were removed by incubation in 20 mM Ammonium Hydroxide. After extensive washing in PBS, untreated cells could then be seeded onto the CM. Figure S7 
Figure legends
